Shanghai Vitalgen BioPharma Co., Ltd. (hereinafter referred to as "Vitalgen" or the "Company") recently announced that VGN-R08b, its independently developed gene therapy product for GBA1 mutation-associated Parkinson's disease (PD-GBA), has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA). The company's other gene therapy product for idiopathic Parkinson's disease, VGN-R09b, previously received this designation in June of this year. With these achievements, both core products in the company's Parkinson's disease portfolio have successfully completed regulatory filings in both China and the United States and have each been granted FTD, underscoring the high recognition of the company's innovative capabilities in neurological disorders by international regulatory authorities. VGN-R09b's clinical trial for idiopathic Parkinson's disease conducted at Beijing Aerospace Center Hospital has also been featured by Beijing Satellite TV due to its favorable therapeutic outcomes.
Based on two innovative therapies with distinct mechanisms of action, VGN-R09b (previously granted FTD) and VGN-R08b (the subject of this latest designation) together constitute the company's synergistic pipeline strategy in Parkinson's disease, encompassing "core intervention" and "upstream modulation." VGN-R09b targets the core pathological aspects of the disease, focusing on functional restoration of the dopaminergic pathway and neuroprotection to achieve comprehensive intervention at both the neural circuit and cellular levels. VGN-R08b, in contrast, targets upstream regulatory mechanisms by modulating lysosomal function and degrading α-synuclein, thereby intervening in disease progression at its source—genetic mutations and abnormal protein aggregation. This combination strategy provides a comprehensive treatment approach addressing distinct aspects of Parkinson's disease pathology. The granting of FTD for VGN-R08b not only affirms its therapeutic potential in addressing the significant unmet medical need in PD-GBA but also validates the company's overarching R&D strategy and scientific approach in Parkinson's disease.
Fast Track Designation (FTD) is a key policy established by the FDA to accelerate the development of promising drugs intended to treat serious conditions. Receiving this designation enables drug developers to engage in more frequent and timely communication with the FDA and supports rolling submission of a Biologics License Application (BLA) upon meeting eligibility criteria, thereby optimizing development efficiency and shortening review timelines. If subsequent clinical data are positive, the product may also be eligible for further accelerated approval pathways such as Priority Review.
Dr. Zhao Xiaoping, CEO of the company, stated, "Having two of our Parkinson's disease gene therapy products receive Fast Track Designation from the U.S. FDA within a matter of months represents significant recognition of our R&D strategy and the execution capabilities of our team. Our product portfolio, built around the dual mechanisms of 'core intervention' and 'upstream modulation,' reflects our systematic R&D approach in Parkinson's disease. Leveraging the review and communication advantages provided by FTD, we will actively advance the global clinical development of VGN-R09b and VGN-R08b, striving to bring these two differentiated innovative therapies to patients worldwide as soon as possible."
About VGN-R08b
VGN-R08b is a gene therapy product independently developed and manufactured by the company, utilizing a recombinant AAV vector. Administered via intracerebroventricular injection, it precisely delivers the functional GBA1 gene to patients' neurons and glial cells. This enables the cells to continuously produce functional GCase protein, which replaces the mutated endogenous GCase, degrades pathologically accumulated glucocerebrosides, thereby restoring neuronal function and alleviating central nervous system involvement. The product is designed to improve patients' disease symptoms at the etiological level.